Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 37/2026 September 13, 2026
- Reading the DNA Fingerprints of Prostate Cancer September 12, 2026
- Phase 1/2 Trial Results for Tinengotinib (TT-00420) in mCRPC September 12, 2026
- STAMINA: Supervised Exercise and Dietary Advice Cut ADT-Related Decline in Prostate Cancer September 8, 2026
Phase 3 Trial of BMS-986365
/in Clinical Trial, Metastatic, Phase 3/by MaxA New Hope for Aggressive Prostate Cancer: Evexomostat’s Potential
/in Preclinical Research/by MaxNXP800: A Promising New Drug for Hormone-Resistant Prostate Cancer
/in Preclinical Research/by MaxDrug Repurposing Against Metastasis?
/in Drug repurposing, Preclinical Research/by MaxPhase 1 Trial of a Polynucleotide Kinase/Phosphatase (PNKP) Inhibitor
/in Clinical Trial, Not PCa related/by MaxPhase 1 Clinical Trial for ADRX-0405 in Advanced Solid Tumors Including Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 trial for ASP1002, a bispecific antibody
/in Clinical Trial, Metastatic, Phase 1/by MaxRethinking Treatment for mHSPC: Insights from Dr. Karim Fizazi
/in Expert Insights, Observational, Retrospective studies/by Max